Search research articles
Contact Us
Filters
Showing results (211-220 of 225) with videos related to
Page
of 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 10, 2009
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
G Capri, J Chang, S-C Chen, et al.
ESMO Open
|
October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial
M V Dieci, G Bisagni, S Bartolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
G Jerusalem, G Mariani, E M Ciruelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
F Di Costanzo, A Sobrero, S Gasperoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H S Rugo, F André, T Yamashita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
R Bartsch, S Frings, M Marty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
M V Dieci, P Conte, G Bisagni, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
August 5, 2021
Skip pattern approach toward the early access of innovative anticancer drugs
G Apolone, A Ardizzoni, A Biondi, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 225) with videos related to
Sort By:
Page
of 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 10, 2009
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
G Capri, J Chang, S-C Chen, et al.
ESMO Open
|
October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial
M V Dieci, G Bisagni, S Bartolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
G Jerusalem, G Mariani, E M Ciruelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
F Di Costanzo, A Sobrero, S Gasperoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H S Rugo, F André, T Yamashita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
R Bartsch, S Frings, M Marty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
M V Dieci, P Conte, G Bisagni, et al.
ESMO Open
|
March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
G Villacampa, T Pascual, F Brasó-Maristany, et al.
ESMO Open
|
August 5, 2021
Skip pattern approach toward the early access of innovative anticancer drugs
G Apolone, A Ardizzoni, A Biondi, et al.
Page
of 23